yet these drugs are not a "home run," says elizabeth loder, md, a professor of neurology at harvard medical school and chief of the division of headache at brigham & women's hospital.
.
fremanezumab has completed phase iii trials and is under review by the fda to prevent migraine and
.
.
we're an independent, student-run newsroom.
.
.
.
.
.
.
erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the